Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Beginning Cash Balance: 2009-2024

Historic Beginning Cash Balance for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to $71.3 million.

  • Anika Therapeutics' Beginning Cash Balance fell 15.37% to $53.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.4 million, marking a year-over-year decrease of 11.72%. This contributed to the annual value of $71.3 million for FY2024, which is 13.22% down from last year.
  • Latest data reveals that Anika Therapeutics reported Beginning Cash Balance of $71.3 million as of FY2024, which was down 13.22% from $82.2 million recorded in FY2023.
  • In the past 5 years, Anika Therapeutics' Beginning Cash Balance registered a high of $157.5 million during FY2020, and its lowest value of $71.3 million during FY2024.
  • For the 3-year period, Anika Therapeutics' Beginning Cash Balance averaged around $82.6 million, with its median value being $82.2 million (2023).
  • In the last 5 years, Anika Therapeutics' Beginning Cash Balance spiked by 76.84% in 2020 and then tumbled by 39.15% in 2021.
  • Yearly analysis of 5 years shows Anika Therapeutics' Beginning Cash Balance stood at $157.5 million in 2020, then crashed by 39.15% to $95.8 million in 2021, then declined by 1.49% to $94.4 million in 2022, then fell by 12.91% to $82.2 million in 2023, then dropped by 13.22% to $71.3 million in 2024.